Background
This ruling forms part of a wider piece of work on ads relating to low testosterone, identified for investigation following complaints and intelligence gathered by our Active Ad Monitoring system, which uses AI to proactively search for online ads that might break the rules. See also related ruling published on 26 August 2026.
Summary of Council decision:
Three issues were investigated, all of which were Upheld.
Ad description
Four poster ads and two paid-for Facebook ads for Voy, an online healthcare provider, seen in January 2026:
a. The first poster featured large text that stated “It’s not him, it’s his hormones”. Smaller text underneath stated “Low sex drive? Lost his spark? He might have low testosterone. Get an at-home test”. In the bottom-right corner it stated “£20 at-home blood test” and “Code TUBE”. Small text beneath it stated “£20 at home blood test with code TUBE. Valid 28/12/25 – 28/02/26. One per customer. UK only. Not combinable with other offers. T&Cs apply”.
b. The second poster ad featured large text that stated “Men get hormonal too”. Smaller text underneath stated “Feeling irritable? It might be low testosterone. Get an at-home test”. The Voy logo appeared in the top-right corner. Text at the bottom left stated “joinvoy.com/trt”. The remaining text was the same as ad (a).
c. The third poster featured large text that stated “Men, why are you so hormonal?”
Smaller text underneath stated “If you’re feeling fatigued, it might be low testosterone. Get an at-home test”. The remaining text was the same as ad (a).
d. The fourth poster featured large text that stated “Are your men hormones getting the better of you?” Smaller text underneath stated “If you’re feeling fatigued, it might be low testosterone. Get an at-home test.” The remaining text was the same as ad (a).
e. The first Facebook ad, produced in conjunction with MenofManual, a trading name of Voy, had text that stated “Low testosterone sneaks up on 1 in 4 men over 30. More and more men are tackling low testosterone, and as the UK’s biggest testosterone clinic, we’re leading the charge. Here are 5 symptoms of low testosterone to look out for: …”. The ad featured a video of a man unboxing a at-home blood test. The voice-over said, “Low testosterone sneaks up on 1 in 4 men over 30. Here are five signs though that will show you may have healthy testosterone levels.” The video listed good energy levels, healthy libido, good body shape, mental sharpness and positive outlook as signs of balanced testosterone levels. The voice-over went on to say, “Feel like you are missing out on some of these? Well, get yourself a blood test from Manual.” Text below the video in the post stated “JOINVOY.COM/TRT” and “Check Your Levels Today”.
f. The second Facebook ad, produced in conjunction with Jason Fox, featured text that included “Recognising the symptoms of low testosterone is the first step to life-changing support”.
The ad then stated “Low energy”; “No motivation”; “Anxiety”; and “Loss of strength & muscle mass…”. The ad featured a video of a man exercising. On-screen text stated “Former Special Forces Sergeant TV Broadcaster Jason Talks Testosterone with Voy”. Jason said, “I was failing not only at home, but work. And because of that, I found myself spiralling out of control. I was like a terrible person to be around. For me, having strength is about admitting when things aren’t going right. I had to actually have a word with myself. Find out what’s going on inside your body. Because that then starts the journey of you becoming the better version of you. Take a Voy testosterone test and see where you stand.” On-screen text then stated “Today could be life changing”.
Issue
The ASA received four complaints, one of which was from a clinically qualified educator:
1. Three complainants in relation to ad (a), two complainants in relation to ad (b) and two complainants in relation to ads (c) and (d), challenged whether the ads misleadingly attributed low testosterone to a range of common symptoms with many potential causes.
2. The ASA challenged whether ads (e) and (f) misleadingly attributed low testosterone to a range of common symptoms with many potential causes.
3. The ASA challenged whether the claim “Low testosterone sneaks up on 1 in 4 men over 30” in ad (e) was misleading and could be substantiated.
Response
1. & 2. Menwell Ltd t/a Voy said that ads (a) to (f) presented specific symptoms as potentially being caused by a medical condition. They stated further that the ads did not state or imply that the advertised symptoms were definitively caused by low testosterone. They communicated that there was a clinically recognised symptomatic association with low testosterone, therefore low testosterone may be one explanation of the symptoms and it was worth investigating further. They said that was different from attributing the symptoms to low testosterone.
They explained that the language used in the ads was deliberately conditional, using claims such as “might be” and “might have” to indicate a possible cause of the common symptoms. Therefore, the ads avoided causal or diagnostic claims. Instead, they highlighted low testosterone as one possible avenue for further investigation. For example, ad (f) stated “Recognising the symptoms of low testosterone is the first step to life-changing support” and then listed a number of symptoms such as “Low energy” and “No motivation”. They said the ad was framed as symptom recognition and to see, through testing, someone’s status. What it did not do was say that low testosterone definitely caused the symptoms or that low testosterone was the only explanation for them.
They said that despite the conditional nature of the ads, advice issued by The British Society for Sexual Medicine (BSSM) demonstrated, that low testosterone was clinically associated with the symptoms referenced in the ads such as fatigue and low libido.
3. Voy confirmed the claim that “low testosterone sneaks up on 1 in 4 men over 30” communicated, in line with the tone of the ad, that reduced testosterone levels affected one in four men in that age group. They said that was not misleading and was substantiated by academic research. They provided an observational study of 1475 men between the ages of 30 and 79 years. They said that the study showed that 24% of men had testosterone levels below clinical thresholds, which supported the “1 in 4” figure in ad (e).
They said the mean age of UK males over 30, based on the Office for National Statistics (ONS) data, with testosterone levels below clinical thresholds was 54 to 56 years. The mean age from the study provided was 47 and therefore the sampled population was younger than the overall target audience. Nevertheless, the results from the study applied to those over 30 and that is why they used the claim “over 30” in the ad.
They said further that the ad referred to the prevalence of low testosterone levels, not to a clinical diagnosis of testosterone deficiency. Testosterone deficiency was defined by both low levels of testosterone and relevant symptoms. The ad reflected that by highlighting recognisable indicators of low testosterone such as energy and libido, and by prompting users who felt they may be missing out on those, to consider testing. They also said that the wording “sneaks up” reflected the clinical context described in the study. That testosterone levels declined gradually with age and were not routinely measured, which meant reduced levels could go unnoticed.
They said because the study showed that 24% of men in the study, aged between 30 and 79, had testosterone levels below clinical thresholds and because the ad used language showing the gradual and often unnoticed nature of hormonal decline and did not conflate low testosterone with clinical diagnosis, the claim “low testosterone sneaks up on 1 in 4 men over 30” had been substantiated and was not misleading.
Assessment
1. & 2. Upheld in relation to ads (b), (c), (d) and (f)
The ASA acknowledged that complainants were concerned that the ads highlighted common symptoms for which low testosterone might not be the cause. Therefore, the ads misleadingly attributed low testosterone to a range of common symptoms with many potential causes and encouraged men to purchase a test kit on that basis.
Ads (a), (b), (c) and (d), which were posters, posed rhetorical questions such as “Low sex drive?”, “Lost his spark?” and “Feeling irritable?” alongside references to being hormonal and low testosterone. The ads then provided a response which used conditional language such as “might” and “if” in relation to the possibility of having low levels of testosterone. We considered consumers would therefore make a connection between the symptoms listed in the ads, hormonal levels and low testosterone, such that low testosterone levels could be a potential cause for those symptoms. We considered it would be clear to consumers that the ads promoted “an at-home test” and that testing could help consumers find out more about their own testosterone levels, including whether they were low. On balance, we considered that, by presenting a series of questions and using expressly conditional language, consumers would understand that low testosterone was being presented as a reasonably likely explanation, but not the only explanation for the symptoms and would not infer that ads for a testing kit were presenting low testosterone as a definitive diagnosis for any referenced symptoms.
Text in ad (e) referred to “tackling low testosterone and presented the advertiser as a “testosterone clinic”, but did not list any symptoms in the text. The video in ad (e) featured a man posing a series of questions, focused on what healthy testosterone levels would look like and which referenced symptoms such as energy levels, libido, muscle growth and fat loss, mental sharpness and focus. He also stated “Feel like you are missing out on some of these? Well, get yourself a blood test from Manual”, which we considered made clear that consumers could order a blood test as a first step. On balance, we considered that the video used sufficiently conditional language such that consumers would understand from ad (e) that low testosterone levels was being presented as a reasonably likely explanation should someone have experienced a number of the symptoms listed, but not the only explanation for the symptoms and would not infer that ads for a testing kit were presenting low testosterone levels as a definitive diagnosis for any referenced symptoms.
We considered ad (f) would be understood to be a personal testimonial from former special services sergeant and TV broadcaster, Jason Fox. Text in ad (f) initially listed symptoms such as low energy, no motivation, anxiety and strength and muscle loss and did not make any reference to a blood test kit. The testimonial from Jason Fox in the video described challenges such as “failing not only at home, but work” and “spiralling out of control”. Although we acknowledged that Jason Fox stated “Find out what’s going on inside your body. Because that then starts the journey of you becoming the better version of you. Take a Voy testosterone test”, we did not consider that was sufficient to counter the overall impression in ad (f) that low testosterone levels was one possible explanation for his symptoms such that a test could help consumers learn more, but instead ad (f) presented low testosterone levels as the explanation for his symptoms. We therefore considered consumers would infer it had been a definitive diagnosis for his symptoms.
Whilst we did not conclude that ads (a) to (e) presented low testosterone levels as a definitive diagnosis for the symptoms referenced in those ads, we then assessed whether the ads exaggerated the likely connection between the listed symptoms and low testosterone levels, and were therefore misleading on that basis.
The BSSM, an independent research and educational organisation, guidelines on male adult testosterone deficiency stated “Sexual dysfunction, especially low sexual desire, reduced morning and night-time erections, and ED [erectile dysfunction] are prominent, commonly presenting symptoms, particularly suggestive of TD [testosterone deficiency] when associated with each other (LoE [level of evidence] 1, Grade A)” and “Visceral obesity, and reductions in muscle mass and bone mineral density (BMD), are commonly observed (LoE 1, Grade A)”. It further stated, “Less-specific symptoms such as fatigue, sleep disturbance, loss of physical strength, reduced energy and motivation, and depressed mood are often present” (LoE 1, Grade B). In terms of screening for testosterone deficiency, it recommended screening for all men who presented in isolation for erectile dysfunction, loss of spontaneous erections, reduced sexual desire, a Body Mass Index (BMI) greater than 30 kg/m2 or waist circumference greater than 102 cm. In addition it recommended screening for all adult men with consistent and multiple signs of testosterone deficiency but considered it “LoE 3, Grade C”.
Clinical practice guidelines from the Endocrine Society, an independent research and educational organisation, divided symptoms into specific, suggestive and nonspecific. Specific symptoms included incomplete or delayed sexual development, loss of body hair and very small testes. Suggestive symptoms included reduced sexual desire and activity and decreased spontaneous erections/erectile dysfunction. Nonspecific symptoms included decreased energy and motivation, feeling depressed, poor concentration and memory, sleep disturbance or increased tiredness, reduced muscle bulk or strength and increased body fat. They further stated “We recommend diagnosing hypogonadism (a condition in which the body doesn't make enough of the hormone testosterone or enough sperm or both) in men with symptoms and signs of testosterone deficiency and unequivocally and consistently low serum total testosterone and/or free testosterone concentrations (when indicated)”.
The BSSM guidelines explicitly graded how strong the evidence was that a symptom was associated with testosterone deficiency and the level of research behind it and that was reflected in their screening recommendations where symptoms given “LoE (level of evidence) 1, Grade A” only needed to exist in isolation for a screening to be needed. However, any other symptoms had to be “multiple” to warrant a screening and even then the recommendation was considered “LoE 3, Grade C”. The Endocrine Society implied a hierarchy of symptoms by labelling them specific, suggestive and nonspecific. We noted, however, that in terms of diagnosing hypogonadism, which we acknowledged was likely a higher threshold than screening or testing for testosterone deficiency, such as Voy’s service offered, the Endocrine Society did not discriminate between the symptoms but did recommend a diagnosis for men with plural symptoms.
On that basis, we considered that claims such as “Low sex drive? Lost his spark?” in ad (a) and the reference to “healthy libido” in ad (e) were likely to be understood as relating to symptoms or effects sufficiently linked to testosterone levels that they did not, in themselves, materially exaggerate that connection.
Ad (b) referred only to “feeling irritable”. The BSSM listed irritability, alongside depression, sadness and anger, as a sign or symptom suggestive of testosterone deficiency, under the umbrella term “Changes in mood”. Irritability was not mentioned in terms of a specific level of evidence but one of the “Changes in mood” group; depression was listed as a less-specific symptom with (LoE 1, Grade B). The Endocrine Society mentioned irritability as a less specific symptom when summarising published evidence of symptoms and their connection to low testosterone levels. It was not included in its own list of symptoms and signs suggestive of low testosterone. Ads (c) and (d) stated, in isolation, “feeling fatigued”. Fatigue (or tiredness) was mentioned by the BSSM and the Endocrine Society as a “less-specific” or “nonspecific” symptom.
The BSSM only recommended testosterone deficiency screening for fatigue and irritability in conjunction with other symptoms. In addition, the Endocrine Society recommended diagnosing hypogonadism with men who presented with plural symptoms and signs of testosterone deficiency (as well as low serum total testosterone and/or free testosterone concentrations). In that context, we considered that ads (b), (c) and (d) suggested a strong connection between those symptoms and low testosterone levels which was not substantiated.
Ad (e) listed a lack of good energy levels, good body shape, mental sharpness, positive outlook and healthy libido as possible symptoms of low testosterone levels. A lack of healthy libido was referred to by the BSSM as particularly suggestive of testosterone deficiency and the Endocrine Society stated it was a suggestive symptom. Both the BSSM and the Endocrine Society listed reduced energy and motivation, loss of physical strength and depressed mood as less-specific or nonspecific symptoms. The Endocrine Society further cited poor concentration and memory and increased body fat as nonspecific symptoms. We therefore considered that “healthy libido” in isolation was likely to be understood as relating to symptoms or effects sufficiently linked to testosterone levels that it did not, in itself, materially exaggerate that connection. Further, while we did not consider in isolation that symptoms such as good energy levels, good body shape, mental sharpness and positive outlook were sufficiently linked to low testosterone levels, because they were mentioned collectively in ad (e), as well as alongside “healthy libido”, the ad did not materially exaggerate that connection.
Ad (f) referred to “Low energy”, “No motivation”, “Anxiety” and “Loss of strength & muscle mass…”. As mentioned above the BSSM and the Endocrine Society both listed reduced energy and motivation, loss of physical strength and depressed mood as less-specific or nonspecific symptoms. Neither party explicitly mentioned anxiety. While we did not consider, in isolation, that symptoms such as “Low energy”, “No motivation” and “Loss of strength & muscle mass…”. were sufficiently linked to low testosterone levels, because they were mentioned collectively in ad (f), they did not materially exaggerate that connection. However, as the ad mentioned “Anxiety”, the ad suggested a strong connection between that symptom and low testosterone levels which was not substantiated.
Because ads (b), (c), (d) and (f) referenced symptoms and characteristics that in isolation were common and could arise for many reasons, we considered that they exaggerated the likely connection between them and low testosterone levels and were therefore misleading. In addition to that, ad (f) also presented the symptoms without conditional language and was further misleading.
Ads (a) and (e) did not breach the Code. Ads (b), (c), (d) and (f) breached CAP Code (Edition 12) rules 3.1, 3.7, 3.11 and 12.1.
3. Upheld
Ad (e) stated “Low testosterone sneaks up on 1 in 4 men over 30. More and more men are tackling low testosterone...”. We considered that in the context of the ad, which also referenced symptoms and signs of both “low” and “healthy” testosterone levels and “tackling low testosterone”, the claim would be understood by consumers to mean that one in four men over 30 years of age had symptomatic low testosterone levels, which was likely to benefit from some form of medical treatment. We assessed the evidence on that basis.
Voy provided an observational study of 1475 black, Hispanic and white men, aged between 30 and 79 years from Boston, United States, who had participated in a previous community health survey.
Two blood samples were taken from the men, and the levels of testosterone and sex hormone-binding globulin (SHBG) were measured from the blood samples. Symptomatic androgen deficiency (low testosterone) was then defined as those who had a total testosterone level less than 300 ng/dl, a free testosterone level (which was calculated from total testosterone and SHBG) lower than 5 ng/dl and had self-reported symptoms of low testosterone. Symptoms of low testosterone were either specific (low libido, erectile dysfunction or osteoporotic fractures) or non-specific (lethargy, sleep disturbance, depressed mood or low physical performance). To qualify as having symptomatic androgen deficiency the participant had to have one specific symptom or two non-specific symptoms. The results showed that 24% of men had total testosterone lower than 300 ng/dl, 11% had free testosterone lower than 5 ng/dl and 5.6% met the criteria for symptomatic androgen deficiency.
We noted that the study had 1845 as the base sample, but 373 of the men had been excluded because they had not shown any initial symptoms of androgen deficiency. Therefore, while the study showed that 24% of men surveyed had total testosterone lower than 300 ng/dl, because it had already discounted men who had not shown symptoms of androgen deficiency, we considered the 24% was not representative of all men in the sample but only men who had already shown symptoms of androgen deficiency.
The claim “Low testosterone sneaks up on 1 in 4 men over 30” in the ad was unqualified. While the ad did go on to discuss five symptoms of low testosterone levels, it did not make clear that the reference to “1 in 4 men” with low testosterone was based on a study of men preselected on the basis of exhibiting those symptoms. Further to that because the ad implied that “1 in 4 men over 30” had symptomatic androgen deficiency and the study showed only 5.6% met the criteria it was also misleading.
Considering the evidence in its entirety, we did not consider that the ad’s claim “Low testosterone sneaks up on 1 in 4 men over 30”, had been adequately substantiated and concluded that the ad was likely to mislead.
The ad breached CAP Code (Edition 12) rules 3.1 (Misleadingness), 3.7 (Substantiation) and 12.1 (Medicines, medical devices, health related products and beauty products).
Action
Ads (b), (c), (d), (e) and (f) must not appear again in their current form. We told Menwell Ltd t/a Voy to not exaggerate the likely connection between common symptoms and low testosterone levels or present low testosterone levels as a definitive diagnosis for symptoms. Further they should not make claims about the occurrence of low testosterone levels in the male population without adequate substantiation.

